David Hutton

The company has dosed the first patients in a Phase 3 trial evaluating the safety and efficacy of Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia.

Raj Kannan, the new CEO of Aerie Pharmaceuticals, talks with Ophthalmology Times' David Hutton about what's coming down the pipeline for Aerie.

According to a team of investigators at University of California, Berkeley, tests of the drug Antabuse could prove the role of hyperactive retinal cells in blindness, potentially leading to better therapies.

Investigators find that hybrid cells could be a potential therapeutic strategy to treat retinal damage and visual impairment.

Gary Jerkins, MD, a Nashville physician who founded SeaStar Kids in 2010 to help disadvantaged Ukrainian youth, has made 47 trips to Ukraine since 1996 and has hope for its future.

Researchers from the Department of Ophthalmology at the University Hospital Bonn and Deutsches Zentrum für Neurodegenerative Erkrankungen suggest that assessments of the eye’s retina could help to detect a loss of brain substance, i. e. “brain atrophy.” The findings are based on data from the Rhineland Study.

While investigators have found a link between dry eye and depression, the exact reasons behind the link are not immediately known.

According to the company, pegcetacoplan demonstrated continuous and clinically meaningful effects at month 18 in the studies, which also found that treatment effects in DERBY were comparable to OAKS during months 6 to 18. The combined 18-month data show the potential for improving treatment effects over.

Anton Vlasov, DO, moved to the United States in 2001 at the age of 14, but since Russia invaded his homeland last month, the safety of family still living in Ukraine has weighed heavy on his mind.

The study, conducted with Tufts Medical Center, represents a breakthrough showing that Microdose Array Print technology can provide similar benefits of non-preserved medications.

The latest announcement comes after the previously granted ODD for polihexanide in acanthamoeba keratitis by the FDA and EMA.

The company’s iLink therapy for the treatment of keratoconus consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce corneal cross-linking designed to strengthen, stabilize and reshape the cornea.

Lisa Nijm, MD, advises young ophthalmologists on how to find common ground with their preferred practice and find solutions in the negotiation process that will help both parties flourish.

Dongkyun Lang, a biomedical engineering and optical sciences professor, is developing a way to diagnose and treat corneal ulcers that is eight times cheaper and 20 times faster than today's gold standard.

The company’s digital treatment device was proven to be non-inferior to eye patch treatment in a randomly assigned controlled study.

Ultrasonic retinal prosthesis has been achieved by a research group at UCLA. It is a step towards a non-invasive retinal prosthesis that works without invasive eye surgery.

A gift from Bronwyn Bateman, MD, will establish the UCLA Bronwyn Bateman Center for Ocular Genetics at the Stein Eye Institute.

Russian bombs on Wednesday struck a hospital in Mariupol, Ukraine, damaging several buildings, including an ophthalmology department. Elsewhere, physicians are participating in relief efforts.

A complete understanding can help ophthalmologists get better results for their patients.

Investigators studying old flies have gained some new insight into retinal degeneration, seeking an understanding "of the molecular mechanisms that drive age-associated changes and the external and internal factors that influence them.”

Bennie H. Jeng, MD, a corneal specialist, will assume his new role at Penn in July, succeeding Joan O’Brien, who will assume a new role as the inaugural director of the Penn Medicine Center for Ophthalmic Genetics in Complex Diseases.

Trial recruitment is enabled by the Foundation Fighting Blindness' patient registry, My Retina Tracker Registry, which includes gene

The clinical trial will evaluate the safety and tolerability of ADX-2191 in patients diagnosed with RP due to mutations of the rhodopsin gene, including the P23H gene mutation.

With a growing rate of childhood myopia, the company's MIRA-4 trial supports a broader RM label for Nyxol in pediatric patients from 3 to 11 years of age.

The company this week is rolling out its Clareon family of IOLs, including Monofocal, PanOptix and Vivity options.

Ameet Goyal, MD, 58, recently pled guilty in the Southern District of New York to all charges for orchestrating a seven-year healthcare fraud scheme by falsely billing for millions of dollars of upcoded procedures, and also for fraudulently obtaining two government-guaranteed loans intended to help small businesses during the COVID-19 pandemic.

In advance of World Glaucoma Week March 6-12, a study of 3826 patients with glaucoma has found significantly higher odds of self-reported difficulty affording medication observed among non-Hispanic African American and Hispanic individuals compared with non-Hispanic White individuals.

The company notes that the system’s design includes a small footprint, enhanced ergonomics, superior imaging, dual-pulsed laser, and advanced astigmatism management tools.

The company’s new technology, which targets the eye’s conventional outflow pathway, is expected to have full commercial availability on April 1.

A team of investigators found that sigma 1 receptor, which is known to protect cells from stress, could turn out to be key to the function and survival of the neurons most impacted by glaucoma.